Influence of sodium monoketocholate on the hypolipidemic activity of lovastatin in healthy and diabetic rats.
Recent findings regarding the physiological transport mechanisms and metabolism of bile acids have led to an increased interest in their synthetic derivatives, especially as transmucous transporters. The aim of this study was to examine the influence of the synthetic sodium salt of monoketocholic acid (Na-MKHA) on the hypolipidemic activity of lovastatin. The effects of a 7 days administration of lovastatin (20 mg/kg b.w.) (experimental group 1, n=5) and a combination of lovastatin (20 mg/kg b.w.) and Na-MKHA (2 mg/kg b.w.) (experimental group 2, n=5) in group of healthy and diabetic male Wistar rats were investigated. The animals in the control group of healthy (n=5) and diabetic (n=5) rats were treated with physiological saline (10 ml/kg b.w.) per os twice a day. In the healthy rats, lovastatin increased the low density lipoprotein (LDL) (32.14%) and non-high density lipoprotein (HDL) (15.38%) cholesterol and decreased HDL cholesterol levels (9.89%), and also increased the investigated atherogenic ratios. Na-MKHA significantly potentiated lovastatin activity, and its effects on the LDL (p<0.05; 102.70%), HDL (p<0.01; 32.93%) and non-HDL (p<0.05; 65%) cholesterol levels, as well as the LDL/HDL (p<0.02; 231.11%), total cholesterol/HDL (p<0.02; 70.52%) and non-HDU/HDL cholesterol ratios (p<0.02; 167.12%). In diabetic animals, the potentiating effect of Na-MKHA was not significant. The stimulatory effect of Na-MKHA is probably a consequence of the intensified transmembrane transport of lovastatin due to the direct action of bile acids on the cell membranes, as well as a result of their enhanced transport via specific bile acid transport systems.
Kojic-Damjanov
Suncica
S
Institute of Laboratory Medicine, Clinical Center of Voivodina, Novi Sad, Republic of Serbia. s.kojic@neobee.net
Djeric
Mirjana
M
Mikov
Momir
M
Kuhajda
Ksenija
K
Kevresan
Slavko
S
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood*; D008055:Lipids / Q000097:blood*; D008148:Lovastatin / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D014280:Triglycerides; D002635:Chenodeoxycholic Acid; C025576:3,7-dihydroxy-12-oxocholanoic acid; D008148:Lovastatin
Atherosclerosis. 1998 Aug;139(2):291-9
9712335
J Lipid Res. 2003 May;44(5):943-52
12562847
Am J Physiol. 1991 Apr;260(4 Pt 1):G625-30
2018137
Toxicol Sci. 2005 Jan;83(1):114-25
15496497
Atherosclerosis. 2004 Aug;175(2):325-31
15262189
J Pharmacol Toxicol Methods. 2004 Nov-Dec;50(3):231-5
15519910
Br J Pharmacol. 2000 Nov;131(6):1179-87
11082126
Atherosclerosis. 1998 Sep;140(1):15-24
9733211
J Lipid Res. 2002 Jan;43(1):2-12
11792716
J Lipid Res. 1997 Feb;38(2):373-90
9162756
Carcinogenesis. 2007 May;28(5):940-6
17183066
Cancer Res. 2007 Feb 1;67(3):863-7
17283114
Farmaco. 2005 Nov-Dec;60(11-12):884-93
16226752
J Hepatol. 2006 Aug;45(2):337-8
16793167
J Hepatol. 2007 Sep;47(3):434-5
17624466
J Am Coll Cardiol. 2003 Sep 17;42(6):1091-7
13678936
Vascul Pharmacol. 2006 Feb;44(2):75-89
16337220
Gastroenterology. 1985 Jan;88(1 Pt 1):192-205
2981081
Biochim Biophys Acta. 1995 Jan 3;1254(1):7-12
7811749
Am J Cardiol. 2006 Apr 15;97(8):1198-205
16616026
Lipids. 1999 Dec;34(12):1327-32
10652993
J Mol Biol. 2007 Jun 1;369(2):439-50
17434532
Biochem Biophys Res Commun. 2007 Jun 8;357(3):707-11
17448444
Prostaglandins Other Lipid Mediat. 2005 May;76(1-4):59-73
15967162
Metabolism. 1999 May;48(5):618-26
10337863
Biochim Biophys Acta. 2005 Jun 15;1735(1):59-67
15951237
Int J Pharm. 2003 Jan 16;250(2):359-69
12527163
Eur J Pharm Sci. 2000 Apr;10(2):133-40
10727879
J Investig Med. 1995 Oct;43(5):443-50
8528755
Biochem Pharmacol. 2003 Aug 15;66(4):565-77
12906921
Hepatology. 2006 Aug;44(2):478-86
16871584
J Control Release. 2005 Jun 20;105(1-2):1-15
15894393
Free Radic Biol Med. 2006 Jun 1;40(11):2005-17
16716901
Proc Natl Acad Sci U S A. 1985 Nov;82(21):7419-23
3903753
Clin Chem. 1972 Jun;18(6):499-502
4337382
Pflugers Arch. 2004 Nov;449(2):123-31
15578267
FEBS Lett. 1999 Jun 11;452(3):160-4
10386582
Proc Natl Acad Sci U S A. 1980 Jul;77(7):3957-61
6933445
Toxicol Lett. 2001 Mar 31;120(1-3):369-77
11323196
Toxicol Sci. 2006 May;91(1):150-8
16452108
J Nutr Biochem. 2005 Dec;16(12):722-8
16169202
J Lipid Res. 1970 Nov;11(6):583-95
4100998
Digestion. 2004;70(2):79-83
15375335
J Lipid Res. 2002 Apr;43(4):533-43
11907135
J R Coll Physicians Edinb. 2002;32(2):134-42
12434795
Atherosclerosis. 1996 Jul;124(1):95-102
8800497